Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults \[[@B1],[@B2]\]. Despite multimodal treatment consisting of maximal safe resection followed by radiation and chemotherapy, tumors recur with a median time to progression of approximately 7 months leading to a median survival of about 15 months \[[@B3],[@B4]\]. In recent years, many of the molecular pathways involved in the initiation and promotion of GBM have been unraveled \[[@B5],[@B6]\], yet no superior treatment strategy could be deduced from those studies. In particular, neither antiangiogenic \[[@B7]\] nor immune-stimulating \[[@B8]\] treatments have been successful in clinical studies so far. Recently, D,L-methadone has been put forward as a potential approach to improved adjuvant treatment in GBM. In fact, Friesen *et al*. \[[@B9]\] showed that D,L-methadone mediates enhanced apoptosis and increased sensitivity toward doxorubicin in established GBM cell lines by reversing deficient caspase activation and reducing intracellular cAMP levels. Furthermore, a recent retrospective report from 27 recurrent GBM patients treated with increasing D,L-methadone concentrations implies a moderate toxicity, while no efficacy data were reported due to the absence of a control arm in this study \[[@B10]\]. D,L-methadone is a μ-opioid receptor agonist, stimulating inhibitory G~i~-proteins, which in turn block adenylyl cyclase activity, followed by an decrease of cAMP levels \[[@B11]\]. cAMP acts as second messenger targeting the cAMP-dependent PKA, either inhibiting or activating the MAPK depending on the biological context of the targeted cells \[[@B12]\]. Consequently, the hallmark of cAMP interference is the ability to inhibit cell growth and induce apoptosis in one cell type, while enhancing cell growth and inhibiting apoptosis in another \[[@B13]\]. It is therefore conceivable, that individual GBM cells treated with D,L-methadone show different treatment sensitivity with respect to cell growth and survival. Although doxorubicin has great impact in the treatment of breast cancer \[[@B14]\], lymphoma \[[@B15]\] or hepatocellular carcinoma \[[@B16]\], it was shown to have only limited clinical efficacy in malignant gliomas \[[@B17]\]. Although this drug is efficacious *in vitro*, poor penetration of the blood--brain barrier \[[@B18]\] and severe neurotoxic side effects \[[@B19]\] prevented its implementation into the treatment portfolio for GBM. The aim of this study was to investigate the μ-opioid receptor expression as the target of D,L-methadone and to validate existing efficacy results of D,L-methadone reported in the previous studies utilizing a panel of patient-specimen derived, molecularly well-characterized cell lines cultured under stem cell promoting conditions (brain--tumor initiating cells; BTICs) in addition to established cell lines to account for the inherent heterogeneity of GBM cell lines. Finally, we investigated the potential interaction of D,L-methadone with temozolomide (TMZ) as a clinically relevant chemotherapy backbone.

Materials & methods {#S0001}
===================

Patient specimen derived & established glioblastoma cell lines (BTIC) {#S0002}
---------------------------------------------------------------------

The BTICs (BTIC-7, 12, 13 and 18) were established from resected, human glioblastoma as previously described \[[@B20]\] and were transcriptionally characterized according to the Verhaak classification \[[@B21]\]. BTIC-7 and BTIC-18 were classified as proneural; BTIC-12 and BTIC-13 as mesenchymal subtype. U87 and U251 cells were used for a comparison of BTICs with established human glioblastoma cell lines ([Table 1](#T1){ref-type="table"}). Experiments were approved by the local ethics committee (University of Regensburg, protocol No.05/105).

###### **Characteristics of patient specimen derived glioblastoma multiforme cell lines.**

  **ID**    **Gender**   **Age**   **GBM type**   **Transcriptional subtype**   **MGMT promoter methylation status**   **IDH1 mutation status**
  --------- ------------ --------- -------------- ----------------------------- -------------------------------------- --------------------------
  BTIC-7    f            53.02     Primary        Proneural                     Unmethylated                           Wild-type
                                                                                                                       
  BTIC-12   m            46.82     Primary        Mesenchymal                   Unmethylated                           Wild-type
                                                                                                                       
  BTIC-13   m            42.38     Primary        Mesenchymal                   Unmethylated                           Wild-type
                                                                                                                       
  BTIC-18   m            50.01     Primary        Proneural                     Unmethylated                           Wild-type

BTIC: Brain tumor initiating cell; GBM: Glioblastoma multiforme.

Cell culture & treatment {#S0003}
------------------------

U87 and U251 glioblastoma cells were grown in Dulbecco\'s Modified Eagle\'s Medium (DMEM) (Biochrom/Millipore, Berlin, Germany, \#F0415) supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin and 50 mg/ml streptomycin (Biochrom/Millipore, \#2213) and 2 mM L-glutamine (Biochrom/Millipore, \#K0283). The BTICs were cultured in RHBA-based serum-free culture media (Takara, \#Y40001) supplemented with 20 ng/ml of the mitogens EGF (Miltenyi Biotec, Bergisch Gladbach, Germany,  \#130--097--751) and bFGF (Miltenyi Biotec, \#130--093--842) and 50 U/ml penicillin, and 50 mg/ml streptomycin (Biochrom/Millipore, \#2213), as described \[[@B20]\]. All glioblastoma cell lines were cultured in a humidified atmosphere of 5% CO~2~ and 95% air. D,L-methadone hydrochloride was dissolved in sterile distilled water (Hospital Pharmacy, University Hospital Innsbruck, Austria), and applied at concentrations of 0.3, 1, 15, 30 and 45 μg/ml. To investigate a potential interaction with TMZ, cells were treated with TMZ alone (Sigma Aldrich, St. Louis, MO, USA,  \#T2577) dissolved in DMSO at 100 μmol/l or in combination with the above-mentioned concentration of D,L-methadone.

Western blot {#S0004}
------------

Cells were harvested by mild trypsination, washed twice in 1 × PBS and centrifugated at 100 × *g*. After cell lysis in a buffer containing 8 M urea, 0.5% Triton × 100, 0.1 M DTT and 40 μl 25 × protease inhibitor cocktail (complete, Sigma-Aldrich), 50 μg protein was loaded per lane on a 12% SDS PAGE gel and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Little Chalfont, UK) by the application of 100 mA for 75 min. Unspecific binding sites were blocked with 5% dry milk dissolved in TBS--Tween buffer. To detect the expression of μ-opioid receptor, we have tested a series of different antibodies. The best signal to noise ratio was achieved using a polyclonal rabbit antihuman μ-opioid receptor antibody (ABCAM, Cambridge, UK, \# 137460) at a concentration of 1:750. Immunoblots were developed with enhanced chemiluminescence kits (Amersham).

Immunofluorescence staining {#S0005}
---------------------------

Cells were grown on coverslips and fixed using freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffer (pH 6.9) for 1 h. Cells were washed three-times in 1 × PBS and subsequently preincubated in a solution containing 1% normal goat serum, and 0.3% Triton X-100 to block nonspecific binding sites. Primary antibody binding was performed by incubating the cells at 4°C overnight to a polyclonal rabbit antihuman μ-opioid receptor antibody (ABCAM, Cambridge, UK) at a concentration of 1:500 in blocking solution. Control slides were incubated in nonimmunized IgG at the identical protein concentration as the primary antibody. Specific binding of the primary antibody was detected by incubation in a biotinylated antirabbit secondary antibody at a concentration of 1:300 for 2 h at room temperature, followed by exposure to streptavidin--FITC at a concentration of 1:300 for 2 h at room temperature (Vector).

Crystal violet assay {#S0006}
--------------------

Cells were seeded in 100 μl DMEM (established cell lines) or in RHBA-based serum-free culture medium (BTICs) at a density of 30,000 cells/well in a 96-well dish plate. After allowing the cells to attach for 24 h, the medium was removed and treated with different concentrations (0.3, 1, 15, 30 and 45 μg/ml) of D,L-methadone, alone or in combination with 100 μM TMZ. A total of 140 h after treatment with different concentrations, the medium was removed and 50 μl of 0.5% crystal violet staining solution was added to each well and incubated for 10 min at room temperature as described previously \[[@B22]\]. The medium was removed, and the plate was washed five-times in tap water steam. Subsequently, the plates were left to air-dry for at least 2 h at room temperature. For quantification of cell viability, 50 μl sodium citrate was added to each well and measured at 550 nm with a plate reader (Varioscan, Thermo Scientific).

Apoptosis FACS analysis {#S0007}
-----------------------

Cells were seeded in 2000 μl DMEM or in RHBA-based serum-free culture medium at a density of 50,000 cells/well in a 6-well dish plate. As the control for D,L-methadone treatment, untreated cells were used. As a control for the TMZ in combination with D,L-methadone, the culture medium was supplemented with equimolar concentrations of DMSO. A total of 140 h after treatment with different concentrations, cells were harvested by trypsination. After 3 min, the cells were collected in culture medium to terminate the enzyme activity. Subsequently, the cells were centrifugated (3 min, 100 × *g*, 4°C) and washed with cold PBS. The supernatant was removed, and the cells were resuspended in 75 μl Annexin solution (5 μl Annexin V-FITC and 70 μl binding buffer; both ImmunoTools, \#31490013). After 20 min incubation on ice and in the dark 200 μl binding buffer was added to cells. 1--2 min before flow cytometric analyses diamine-2-phenylindol (DAPI; Sigma \#D9542) was added to a final concentration of 5 μg/ml. All flow cytometric analyses were performed using the FACSCanto-II flow cytometer (BD Biosciences) using standard optical configurations provided by the manufacturer. Briefly, Annexin-FITC and DAPI staining was detected using a 530/30 bp and a 450/40 bp filter, respectively. Due to independent violet and blue laser excitation (405 and 488 nm, respectively) compensation was not required. The data acquisition and analysis were performed with FACSDiva software (Ver. 7.0, BD Bioscience). This assay relies on the following assumption: apoptotic cells will bind Annexin V, but still exclude DAPI for a period of 4--6 h. Thus, a read out positive for annexin V but negative for DAPI was defined as specific apoptosis.

Statistical analysis {#S0008}
--------------------

Results were expressed as mean values plus standard deviation. Differences between groups were calculated by computing one-way ANOVA followed by *post hoc* testing (Holm--Sidack method). Significance was defined as p \< 0.05 (SigmaPlot, version 13.0; Systat Software).

Results {#S0009}
=======

μ-opioid receptor expression {#S0010}
----------------------------

Western blotting revealed immunoreactive bands predominantly with a molecular weight of 51 kDa in all tested cell lines. We did not detect any significant quantitative difference in the μ-opioid receptor expression between the cell lines ([Figure 1](#F0001){ref-type="fig"}A). Immunofluorescence labeling showed an intense, patchy and partly clustered staining pattern, which was predominantly associated with the plasma membrane and within cell processes ([Figure 1](#F0001){ref-type="fig"}B). This pattern was similar in all tested cell lines. Replacing the primary antibody with nonimmunized IgG at the identical protein concentration revealed very low background staining ([Figure 1](#F0001){ref-type="fig"}C). Additional control experiments omitting the primary antibody and secondary antibody also resulted in minimal background staining confirming the specificity of the staining results (data not shown).

![**Expression of the μ-opioid receptor in glioblastoma multiforme cells.**\
**(A)** Western blotting experiments detected a protein with a molecular size of 51 kDa, which corresponds to a glycosylated form of the receptor with a predicted size of 43 kDa \[[@B23]\]. No significant difference in the expression levels were detected between the tested cell lines. **(B)** Immunofluorescence staining of the BTIC-18 cell line revealed a clustered, patchy expression pattern, associated with the plasma membrane as well as cell processes. There was no difference in the staining results between all cell lines. **(C)** Application of nonimmunized rabbit IgG in control slides induced minimal background staining confirming the specificity of the antibody labeling.\
BTIC: Brain tumor initiating cell.](cns-07-18-g1){#F0001}

Cell viability {#S0011}
--------------

Although all GBM cell lines showed a decrease of cell viability in a dose dependent fashion after treatment with higher concentration of D,L-methadone alone (15--45 μg/ml; [Figure 2](#F0002){ref-type="fig"}), we observed a differential susceptibility of the tested cell lines, with BTIC-7 (proneural) responding with the highest and BTIC-12 (mesenchymal) with the lowest sensitivity to D,L-methadone. At a concentration of 1 μg/ml, we did not detect any reduction of cell viability except for U87, and at 0.3 μg/ml, which corresponds to the maximal concentration which could be reached during clinically tolerable dosage, there was no induction of cell death, in fact, we even observed a significantly increased cell viability in BTIC-18 (proneural, [Figure 2](#F0002){ref-type="fig"}). Positive interaction between TMZ and D,L-methadone were observed only in higher concentrations of D,L-methadone; in BTIC-7 starting at 15 μg/ml ([Figure 3](#F0003){ref-type="fig"}), at 45 μg/ml in U251, BTIC-13 and BTIC-18 ([Figure 3](#F0003){ref-type="fig"}); BTIC-12 showed no interaction with TMZ ([Figure 3](#F0003){ref-type="fig"}). Interestingly in U87, we detected a significantly antagonistic effect of D,L-methadone to TMZ in concentrations from 1 to 30 μg/ml ([Figure 3](#F0003){ref-type="fig"}).

![**Effects on cell viability (in percent of untreated control) by D,L-methadone alone on all tested glioblastoma multiforme cell lines.**\
**(A)** At 0.3 μg/ml D,L-methadone, cell viability is significantly increased in BTIC-18. **(B)** At concentrations of 1 μg/ml significant cell killing was observed only in U87. **(C--E)** At higher concentrations, BTIC-7 showed the highest and BTIC--12 the lowest susceptibility. The asterisk (\*) indicates significant differences to untreated control (significance level 0.05).\
BTIC: Brain tumor initiating cell.](cns-07-18-g2){#F0002}

![**Interaction between D,L-methadone and temozolomide.**\
Glioblastoma cell lines (two established, four BTICs) were treated with 0.3, 1, 15, 30 and 45 μg/ml D,L-methadone alone (solid lines), or in combination with TMZ (100 μM, dashed lines). After 140 h of treatment, cell viability was determined by crystal violet assay. The asterisk (\*) indicates significant effects of D,L-methadone alone compared with the untreated control, whereas the double asterisk (\*\*) indicates significant changes to TMZ alone (significance level 0.05). All experiments were repeated at least two-times.\
TMZ: Temozolomide.](cns-07-18-g3){#F0003}

Apoptosis {#S0012}
---------

The BTICs showed significant induction of apoptosis upon D,L-methadone treatment alone exclusively at concentrations of 45 μg/ml ([Figure 4](#F0004){ref-type="fig"}). In contrast, the established cell lines U251 and U87 showed an increased fraction of apoptotic cells when treated with concentrations starting from 1 μg/ml (U251) to 15 μg/ml (U87), respectively ([Figure 4](#F0004){ref-type="fig"}). Positive interaction with TMZ on the induction of apoptosis occurred in the BTICs exclusively in the proneural cell lines (BTIC-7 starting at 30 μg/ml and BTIC-18 at 45 μg/ml; [Figure 4](#F0004){ref-type="fig"}) whereas in the mesenchymal cell lines (BTIC-12 and BTIC-13 [Figure 4](#F0004){ref-type="fig"}) no interaction with TMZ was observed. In contrast, the adherent cell lines U87 and U251 displayed positive interaction with TMZ starting at concentrations of 1 and 15 μg/ml, respectively ([Figure 4](#F0004){ref-type="fig"}).

![**Induction of apoptosis detected by FACS analysis.**\
Treatment with 0.3, 1, 15, 30 and 45 μg/ml D,L-methadone alone (solid lines), or in combination with TMZ (100 μM, dashed lines). The asterisk (\*) indicates significant effects of D,L-methadone alone compared with the untreated control, whereas the double asterisk (\*\*) indicates significant changes to TMZ alone (significance level 0.05). In the BTICs, significant induction of apoptosis was observed only at high concentrations of D,L-methadone alone compared with untreated control, whereas the established cell lines showed increased rates of apoptotic cells at concentrations starting from 1 μg/ml (U251) to 15 μg/ml (U87). Interaction with TMZ occurred in the BTICs exclusively in the proneural cell lines (BTIC -- 7 & 18) at higher concentrations (30/45 μg/ml), whereas the established cell lines showed positive interaction at concentrations starting from 1 μg/ml (U87) to 15 μg/ml (U251).\
BTIC: Brain tumor initiating cell; TMZ: Temozolomide.](cns-07-18-g4){#F0004}

Discussion {#S0013}
==========

The treatment of GBM still remains a formidable challenge. Despite significant progress in the understanding of the molecular pathogenesis no adjuvant treatment options besides radiochemotherapy have been established for this disease so far \[[@B3],[@B4]\]. One reason for the dismal prognosis may be the inherent resistance to adjuvant therapy such as radiation and chemotherapy \[[@B24],[@B25]\], By the search for improved treatment results, D,L-methadone has been suggested as an agent, which may sensitize tumor cells including GBM to genotoxic treatment regimen \[[@B9],[@B26]\]. Due to its agonistic actions on the μ-opioid receptor \[[@B30]\], D,L-methadone has been widely used for the treatment of cancer patients with insufficient analgesia \[[@B31]\]. In addition, the activation of μ-opioid-receptors by D,L-methadone leads to a G-protein coupled decrease of intracellular cyclic AMP, a second messenger regulating gene transcription, cellular proliferation and apoptosis \[[@B11],[@B32],[@B33]\]. Previous studies reported the presence of μ-opioid receptors in glioma cells \[[@B34]\], and demonstrated increased apoptosis in U118MG and A172 glioblastoma cell lines when treated with D,L-methadone and doxorubicin in combination \[[@B9]\]. However, there are several aspects which may interfere with the potentially successful application of D,L-methadone in GBM patients. First, D,L-methadone is extensively metabolized in the liver with an average half-life time of about 24 h \[[@B35]\]. For adequate efficacy in substitution therapy of opioid addicts, a daily dosage between 60 and 120 mg/day is required. With this regimen, plasma concentrations of only 0.58 μg/ml were reported \[[@B36]\]. This was confirmed by a study by Mohamad *et al*. reporting plasma levels between 0.15 and 0.6 μg/ml under maximal dosage \[[@B37]\]. A more recent study investigating the steady-state pharmacokinetics of (D) and (L) methadone concluded 0.251 ng/μl for the (L) and 0.303 μg/ml for the (D) enantiomer \[[@B38]\]. Second, as indicated by radio-labeled tracer studies, D,L-methadone shows a penetration of the blood--brain barrier of only about 42% \[[@B39],[@B40]\]. Thus, with a tolerable plasma maximum of 0.6 μg/ml methadone, only a concentration of about 0.25 μg/ml could be achieved in the interstitial space of the brain. In addition, methadone is a substrate of the P-glycoprotein extrusion pump, which has been shown to be stereoselective for methadone and other compounds \[[@B41]\]. In GBM tissue, a significant overexpression of the P-glycoprotein efflux pump has been demonstrated and linked to the notorious resistance to systemic antitumor treatment of this disease \[[@B42],[@B43]\]. It is therefore conceivable that the *in vivo* concentrations of methadone are even lower in GBM patients compared with nontumorous brain tissue, which was the subject of recent forensic studies investigating tissue concentrations of D and L methadone in the human brain \[[@B44]\]. A first study on the clinical feasibility of D,L-methadone in patients with recurrent GBM has used an ascending dosing protocol of D,L-methadone up to a maximum of 20--35 mg/day \[[@B10]\], which is about half of the dosage used in opioid addicts. Although in this study, the observed D,L-methadone-related toxicity was rather moderate and the 6-month progression free survival was found comparable to historic controls, the putative concentrations of D,L-methadone in the brain with this dose regimen are presumably significantly lower compared with the concentrations found effective in the *in vitro* study on GBM cells by Friesen and co-workers \[[@B9]\]. Third, the effects of cAMP alterations due to D,L-methadone can either be proapoptotic and antiproliferative or antiapoptotic and proproliferative. Different effects can most likely be attributed to different dosages and the biological context of the treated cell line \[[@B12],[@B13]\]. Given the extensive heterogeneity of GBM \[[@B45],[@B46]\], it is conceivable that D,L-methadone treatment may cause entirely unpredictable effects in the individual GBM patient, which is suggested by the data revealed in this study. In addition, the primary mode of action of D,L-methadone is still incompletely understood. For example, it remains unclear whether the μ-opioid receptor is exclusively responsible for the observed effects or whether additional binding sites are required \[[@B47]\]. We found a significant discrepancy in the susceptibility of the tested cell lines with the proneural primary cell lines responding with highest and the mesenchymal with the lowest sensitivity. Based on the pharmacokinetic evidence outlined above, we tested a concentration of D,L-methadone of 0.3 μg/ml, which surprisingly induced an improved cell viability in one cell line (BTIC-18, proneural). All other cell lines did not display any effects at all in this clinically relevant concentration. As for a positive interaction with TMZ, which would be a feasible chemotherapy backbone in GBM treatment, we observed significant effects of D,L-methadone only at concentrations of 15 μg/ml and higher, which are unlikely to be reached given the actual pharmacokinetics of D,L-methadone in the brain. In addition, the established cell line U87 displayed significantly antagonistic effects of D,L-methadone at concentrations between 1 and 30 μg/ml. Our results regarding the μ-opioid receptor expression indicated no significant difference between the tested cell lines. Thus, heterogeneity of the target expression was ruled out as a potential rationale for the discordant effects, and may not serve as a potential biomarker for a clinical efficacy of D,L-methadone. Interestingly, we found differential effects in the induction of apoptosis compared with the crystal violet testing, which is an established assay for cell viability in this context \[[@B22]\]. Although the established cell lines showed increased apoptosis already at lower concentrations (1 μg/ml), the primary cell lines became not apoptotic at all (mesenchymal subtype) or only at higher dosages (proneural subtype) which is not entirely in correspondence to the cell viability assay results. It is conceivable that this phenomenon can be attributed to different primary read outs of the assays. Although the flow cytometric detection of apoptosis relies on the externalization of phosphatidylserine and the consecutive binding of annexin V \[[@B48]\] as a hallmark of apoptotic cell death, the crystal violet assay quantitatively measures bound dye to proteins and DNA \[[@B22]\] as a viability marker of the remaining cells. Both aspects may be influenced by a differential time series of events, which can explain the differential results in our experiments.

Conclusion {#S0014}
==========

The data indicate that D,L-methadone alone or in combination with TMZ causes increased apoptosis and reduced cell viability only when applied at high concentrations which most likely will not be reached in patients with GBM. When achievable drug concentrations are used, no antitumorigenic effects of D,L-methadone could be observed *in vitro*. In contrast, we even detected either proproliferative or antagonistic effects to TMZ treatment in specific cell lines. Our results strongly suggest caution to the premature use of D,L-methadone in the treatment of GBM patients, and highlight the mandatory requirement of clinical efficacy studies.

###### Summary points

-   D,L-methadone, a μ-opioid receptor agonist, has recently been put forward as a potential approach to improved adjuvant treatment in glioblastoma (GBM) by stimulation of inhibitory G~i~-proteins and reduction of adenylyl cyclase activity with subsequent decrease of intracellular cAMP levels.

-   The hallmark of cAMP level reduction is its ability to induce apoptosis in one cell type and inhibit apoptosis in another, depending on the biological context of the cell.

-   We therefore tested a panel of GBM cell lines, which all showed similar levels of μ-opioid receptor expression, for the efficacy of D,L-methadone alone and the potential interactions with temozolomide (TMZ). We found a significantly different susceptibility between the cell lines with the proneural subtype showing the highest and the mesenchymal the lowest sensitivity.

-   At high concentrations, D,L-methadone induced apoptosis in all cell lines; however, in dosages reflecting clinically attainable concentrations in the brain, D,L-methadone alone showed no efficacy, and induced even higher proliferation in one specific cell line. Also, at this lower dosage, we observed no interactions with TMZ; in contrast, TMZ toxicity was even antagonized in U87 cells by D,L-methadone.

-   Our results suggest caution regarding the premature use of D,L-methadone in the treatment of GBM patients, and highlight the mandatory requirement of clinical efficacy studies.
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